Antibiotic-Resistant Infections Treatment Market Is Expected to Be Worth USD 7,637.5 Million, Growing at A 5.7% CAGR by 2034. Antibiotic-Resistant Infections Treatment Market growth is driven by rising antibiotic resistance, the need for new therapies, and increased public health awareness. Explore factors influencing growth, key players, and future trends in antibiotic resistance solutions.
NEWARK, Del, July 11, 2024 (GLOBE NEWSWIRE) — As per Future Market Insights’ latest industry analysis, the global Antibiotic-Resistant Infections Treatment Market was valued at around US$ 4,154.3 million in 2023 and is anticipated to exhibit a CAGR of 5.7% over the forecast period (2024-2034).
Companies are increasing the number of applications for existing antibiotic drugs and changing the route of administration of these drugs to boost sales in terms of value and volume. Physicians can easily start intravenous therapy at hospitals if the drug availability in oral and intravenous forms remains the same. Intravenous drugs are majorly administered once a day and fluorinated quinolones are widely adopted in the community. The boosted adoption rate of such antibiotics by physicians is likely to augment the antibiotic-resistant infection treatments market during the forecast period.
Request a Sample Copy of This Report!
https://www.futuremarketinsights.com/reports/sample/rep-gb-19735
Most pharmaceutical companies are developing new antibiotics with one or more than one API to provide relief against multi-drug-resistant bacteria and broaden the activity spectrum of drugs. This combination-based product is highly accepted among physicians globally and is likely to propel market growth during the forecast period.
- For instance, in April 2024, the United States FDA approved Pivya, a pivmecillinam tablet, for the treatment of uncomplicated UTIs in female adults. The tablets are useful for fighting the susceptible isolates of Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus
This enhances market growth due to the increasing focus of researchers and manufacturers on the introduction of new combinations of antibiotic drug products against multi-drug-resistant bacteria, which can be indicated for varied indications.
Access to healthcare specialists has expanded because of the practicality and accessibility of telemedicine services. The increase in the number of practitioners offering telemedicine and online services to patients suffering from infectious diseases in remote areas is augmenting the growth of the market.
Key Takeaways from the Antibiotic-Resistant Infections Treatment Market Study:
- By drug class, the Nirtofurans (Nitrofurantoin) will hold a lucrative share value of 22.4% in 2024.
- By route of administration, oral segment will hold the highest segment share in terms of the market share value of 63.0% in 2024.
- By disease indication, the cystitis segment will hold a lucrative share value of 60.9% in 2024, among other disease indications.
- By age group, the adult segment will contribute a lucrative share value of 45.2% in 2024.
- By distribution channel, the retail pharmacies will hold a lucrative share value of 42.1% in 2024.
- South Asia & Pacific will be considered the leading region with a value share of 30.3% in 2024.
“Expanding indications and formulations in existing portfolios with combination products and increased expenditure and research funding is responsible for the growth of the market,” Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.)
Antibiotic-Resistant Infections Treatment Market Competition
Collaboration and expansion among the companies or brands is the key strategy of the leading manufacturers of the market such as Johnson & Johnson (Janssen Pharmaceuticals, Inc.) GlaxoSmithKline Plc (GSK), among others, to enhance their presence in the market and compete with other competitors during the coming years. Following are a few examples of key developments made by them to be at the top position:
- Johnson & Johnson have the J&J Centers for Global Health Discovery, a new global network of specially designed partnerships. The growth was intended to accelerate discovery research against emerging threats of TB, dengue fever, flavivirus, coronavirus, and antimicrobial resistance.
- GSK plc joined as a Founding Partner of the Fleming Initiative in May 2024. This initiative represents a collaborative approach to tackling the global challenge of antimicrobial resistance.
Want more insights?
Future Market Insights brings a comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2019 to 2034. The global antibiotic-resistant infections treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights into antibiotic-resistant infections treatment market segment based on drug class – penicillin and combinations, (piperacillin and tazobactam, pivmecillinam, Ticarcillin/Clavulanate, amoxicillin and Clavulanate potassium), cephalosporin, Colistin, carbapenems, (meropenem and imipenem), fluoroquinolones, aminoglycoside antibiotics, amikacin, gentamicin, (Nirtofurans (nitrofurantoin), Fosfomycin) among others. by route of administration – oral and parenteral, by disease indication – pyelonephritis or cUTI, cystitis, pneumonia among other disease indication, by age group – pediatric, adult, and geriatric, by distribution channel – hospital pharmacies, gynecology and urology clinics, drug stores, retail pharmacies and online drug stores across seven major regions.
Purchase the Full Report Now!
https://www.futuremarketinsights.com/checkout/19735
Leading Antibiotic-Resistant Infections Treatment Manufacturers
- Pfizer Inc.
- Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
- Merck & Co., Inc.
- Glaxosmithkline Plc (GSK)
- F.Hoffmann-La Roche Ltd.
- AbbVie
- AstraZeneca
- Bayer AG
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- Sandoz AG
- Lupin Ltd.
- Advacare Pharma
- Validus Pharmaceuticals LLC
Key Segments of Antibiotic-Resistant Infections Treatment Market Report
By Drug Class:
As per drug class, the market has been categorized into penicillin and combinations, (piperacillin and tazobactam, pivmecillinam, Ticarcillin/Clavulanate, amoxicillin and Clavulanate potassium), cephalosporin, Colistin, carbapenems, (meropenem and imipenem), fluoroquinolones, aminoglycoside antibiotics, amikacin, gentamicin, (Nitrofurans (nitrofurantoin), Fosfomycin) among others.
By Route of Administration:
This segment is further categorized into oral and parenteral.
By Disease Indication:
This disease indication segment is bifurcated into pyelonephritis or cUTI, cystitis, pneumonia among other disease indications.
By Age Group:
This age group segment is bifurcated into pediatric, adult, and geriatric.
By Distribution Channel:
Different distribution channels include hospital pharmacies, gynecology and urology clinics, drug stores, retail pharmacies, and online drug stores.
By Region:
Industry analysis has been carried out in key countries of North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe, and Middle East & Africa.
Author by
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
Have a Look at the Related Report from the Antibiotic-Resistant Infections Treatment Market:
The global antibiotics active pharmaceutical ingredient (API) market is expected to attain a valuation of USD 8653.0 million in 2023 and is projected to reach USD 12002.3 million by 2033
The global veterinary antibiotics market is anticipated to be worth US$ 11,453.3 million in 2023. The veterinary antibiotics market is expected to expand at a sluggish CAGR of 5.8% and reach US$ 20,154.0 million by 2033.
The global Treatment-Resistant Hypertension Management Market is expected to garner a market value of US$ 43 Million in 2023 and is expected to accumulate a market value of US$ 159.41 Million by registering a CAGR of 14%
The Antibiotic susceptibility testing market revenue totaled US$ 2.82 Billion in 2021. The global market is expected to reach a valuation of US$ 4.05 Billion by 2028, expanding at a CAGR of 5.2%.
Worldwide revenue from the global Eye Infections Treatment Market is estimated at US$ 7.3 Billion for 2022, and the market is projected to progress at a CAGR of 3.8% from 2022 to 2030.
Rising at a CAGR of 5.6% from 2022 to 2029, arthropod-borne viral infections testing demand is estimated to attain a valuation of US$ 1.3 Bn by end of the forecast period.
According to Future Market Insights research, during the projected period, the global catheter associated urinary tract infections treatment market is expected to grow at a CAGR of 3.0%.
The global antibiotic drugs market was valued at US$ 43.6 billion in 2022 and is expected to reach US$ 64.9 billion by 2033. The sales of antibiotic drugs are set to gain traction over the forecast years with a CAGR of around 3.7%.
The global Difficile Infections (Clostridium Difficile Associated Disease) Treatment market size is expected to surpass an impressive valuation of US$ 809 Million in 2023
The global helicobacter pylori infections treatment market is expected to surpass an impressive valuation of US$ 638.3 Million in 2023 and is projected to exhibit a compound annual growth rate (CAGR) of 7.04%
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
- Black Opal Insurance Launches Investor-Focused Property Insurance Platform for Real Estate Pros - June 30, 2025
- Camfil Highlights Importance of Summer HVAC Maintenance for Better Learning Environments - June 30, 2025
- American Tungsten Corp. Announces Non-Brokered Private Placement of Shares - June 30, 2025
